Clover Health Investments (CLOV) 44th Annual J.P. Morgan Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
44th Annual J.P. Morgan Healthcare Conference summary
15 Jan, 2026Strategic focus and achievements
Achieved 53% year-over-year Medicare Advantage membership growth to approximately 153,000, with high retention and minimal e-broker exposure.
Maintained industry-leading clinical quality, ranking as the top PPO in Medicare Advantage for HEDIS quality for two consecutive years, with 97% of members in a 4 Star payment year PPO.
Sustained Adjusted EBITDA profitability and targeting GAAP net income profitability in fiscal year 2026.
Four-star payment year and favorable CMS rate updates provide financial tailwinds, with anticipated >$70 PMPM revenue boost in 2026.
Growth strategy centers on technology-driven care management, early disease detection, and disciplined expansion in core markets.
Technology and clinical platform
Core technology, Clover Assistant, leverages AI and interoperability to empower all physicians, not just select groups.
AI-driven platform enables earlier identification and management of chronic diseases, leading to better long-term outcomes and fewer hospitalizations.
Technology is cloud-native, ML-native, and rapidly integrates advancements in foundational AI models.
Platform supports wide PPO networks, delivering HMO-level clinical quality and cost control.
Integrates 100+ data sources and proprietary AI/ML models to support clinical decision-making and improve medication adherence.
Financial and operational outlook
Returning member cohorts are increasingly profitable, with new members expected to approach break-even contribution profit.
High retention, improved SG&A efficiency, and increased Clover Assistant coverage are key profitability drivers.
Self-funded growth model relies on mature cohorts funding new member acquisition and compounding profitability.
Insurance BER improved to 89.4% with 35% YoY MA membership growth as of 3Q25.
Focused on disciplined growth in three to five core states, with technology expansion via Counterpart Health elsewhere.
Latest events from Clover Health Investments
- AI-powered care model delivers top HEDIS scores, rapid growth, and expanding profitability.CLOV
Investor presentation24 Mar 2026 - Strong growth, high retention, and tech-driven care position for 2026 profitability.CLOV
Leerink Global Healthcare Conference 202610 Mar 2026 - Achieved 38% membership and 41% revenue growth in 2025; 2026 targets first GAAP Net Income.CLOV
Q4 202526 Feb 2026 - AI-driven platform, Star Rating gains, and profitability fuel record growth and 2025 expansion.CLOV
43rd Annual J.P. Morgan Healthcare Conference 20253 Feb 2026 - AI-powered platform drives lower medical costs and scalable growth in Medicare Advantage.CLOV
KeyBanc Capital Markets Technology Leadership Forum2 Feb 2026 - First-ever GAAP net income, 11% revenue growth, and raised guidance on margin gains.CLOV
Q2 20242 Feb 2026 - Positive EBITDA, strong cash, and tech-driven care fuel growth and resilience in Medicare Advantage.CLOV
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase2 Feb 2026 - AI-powered platform drives profitability, growth, and new third-party revenue streams.CLOV
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 2024 saw 9% revenue growth, higher EBITDA, and a 4.0 Star PPO plan rating.CLOV
Q3 202416 Jan 2026